Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- White Matter Found in COVID-19 Vaccine Vials Not Contaminant: Pfizer
September 16, 2021
- Heart Failure Med Verquvo Makes Japan Debut: Bayer
September 16, 2021
- Another Patient Dies in Astellas’ Gene Therapy Trial, FDA Issues New Clinical Hold
September 15, 2021
- Taiho Seeks Japan Approval for GIST Drug Pimitespib
September 15, 2021
- Keytruda Filed for RCC Adjuvant Therapy in Japan: MSD
September 15, 2021
- Kyowa Kirin’s G-Lasta Enters Japan PII Study for Stem Cell Transplant
September 14, 2021
- Chugai Lifts Shipment Curbs for Edirol, Easing Active Vitamin D3 Shortages
September 13, 2021
- Choseido’s Cymbalta Generic Now Available in Japan
September 13, 2021
- Court Pitches Settlement in Opdivo Royalty Row, Response Due Sept. 22
September 13, 2021
- Poxel/Sumitomo Dainippon to Launch Twymeeg on Sept. 16
September 13, 2021
- Adcetris Filed for 1st-Line Pediatric Nod for Hodgkin’s Lymphoma
September 13, 2021
- Ayumi Can Make 2 Billion Calonal Tablets Annually, Cover Substitute Demand for Recalled Products: CEO
September 10, 2021
- Sumitomo Dainippon Predicts 20-30 Billion Yen Sales from “Frontier Business” by FY2027
September 10, 2021
- SymBio Starts Nonclinical Study of Brincidofovir IV for Brain Tumors
September 9, 2021
- Kyowa Kirin Bags Japan Rights to AM-Pharma’s SA-AKI Drug
September 9, 2021
- Opdivo/Yervoy Gets First-Line OK for Malignant Pleural Mesothelioma in Taiwan
September 9, 2021
- Mitsubishi Tanabe Launches Global PII Study for Spinal Cord Injury Drug
September 9, 2021
- Rohto, Osaka Univ., and AI Firm to Develop New Solution for Predicting Systemic Diseases from Fundus Data
September 9, 2021
- Shionogi Forms Capital Alliance with Robotic Startup to Develop New Solutions
September 9, 2021
- Drug Makers’ Detailing Activities Collectively Down in July: Intage
September 9, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…